Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 17, Issue 2, Pages 295-304Publisher
IOS PRESS
DOI: 10.3233/JAD-2009-1048
Keywords
(-)-Epigallocatechin-3-gallate (EGCG); 6-Hydroxydopamine (6-OHDA); neuroprotection; Parkinson's disease; signal transducers and activators of transcription (STAT)
Categories
Funding
- National Nature Science Foundation of China [30430280]
- Ministry of Sciences and Technology [2004BA702B02, 2006CB500701, 2006AA02A408, 2008ZX09312-014]
Ask authors/readers for more resources
As a natural product, (-)-Epigallocatechin-3-gallate (EGCG), has demonstrated remarkable neuronal protection by depressing oxidative stress in Parkinson's disease (PD). However, the molecular mechanisms underlying EGCG neuronal protection have not been clarified. Using 6-hydroxydopamine (6-OHDA)-treated human neuroblastoma SH-SY5Y cells as a PD cell model, we found that 6-OHDA can cause neuronal death by regulating the activity of STAT3. Pretreatment of SH-SY5Y cells with EGCG (0.1-10 mu M) significantly attenuated cell death induced by 6-OHDA. In addition, STAT3 activity decline induced by 6-OHDA in SH-SY5Y cells can be completely prevented by the presence of 1 mu M of EGCG, and neuronal cell proliferation can be stimulated by EGCG treatment. These results clearly demonstrate that the disruption of STAT3 signaling by 6-OHDA makes significant contribution to the neuronal death in PD, and the protection of EGCG on neurons against oxidative stress-induced cell death may result from the re-stimulation of STAT3 signaling pathway. Our study not only clarified the role of STAT3 signaling pathway in oxidative stress-induced neuronal cell death, but also identified its involvement in the protection mechanism of EGCG on neurons in PD. The data resulting from our study also suggest that STAT3 may serve as a potential therapeutic target for drug development in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available